Compare GRFS & PI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | PI |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 2006 | 2016 |
| Metric | GRFS | PI |
|---|---|---|
| Price | $8.87 | $163.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.15 | ★ $222.75 |
| AVG Volume (30 Days) | 485.7K | ★ 619.6K |
| Earning Date | 07-28-2022 | 02-05-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,821,017,248.00 | $359,795,000.00 |
| Revenue This Year | $5.36 | $1.30 |
| Revenue Next Year | $5.15 | $22.70 |
| P/E Ratio | $17.46 | ★ N/A |
| Revenue Growth | ★ 7.31 | 4.24 |
| 52 Week Low | $6.19 | $60.85 |
| 52 Week High | $11.14 | $247.06 |
| Indicator | GRFS | PI |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 41.10 |
| Support Level | $8.79 | $168.86 |
| Resistance Level | $9.40 | $215.25 |
| Average True Range (ATR) | 0.24 | 12.30 |
| MACD | -0.05 | -2.21 |
| Stochastic Oscillator | 12.18 | 3.11 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.